Ovid Therapeutics Inc (OVID) Stock Price, Quote & News

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 661 7661

Fax: 646 661 4027

Website: www.ovidrx.com

Address:

441 Ninth Avenue, 14th Floor, New York, United States

SupremeElite Mar. 22 at 12:33 AM

$OVID

0 · Reply

LamboRush Mar. 21 at 3:25 PM

$OVID solid move so far

0 · Reply

FriendOfmy Mar. 21 at 4:23 AM

$OVID Offering at $2.01 folks ! Be careful folks pps will head back down to low 2’s

0 · Reply

Doom_Gloom_AR Mar. 20 at 11:31 PM

$OVID rerate time!

0 · Reply

AltradoLinguini Mar. 20 at 7:57 PM

$OVID This thing feels like it’s really about to blow into AH with virtually no major volume resistance because it’s so under the radar by comparison to peers. GLTA! 🍀🍀🍀

0 · Reply

anachartanalyst Mar. 20 at 6:02 PM

$OVID https://anachart.com/wp-content/uploads/ana_temp/1774029712_soc-img.jpg

0 · Reply

luccichio Mar. 20 at 5:56 PM

$OVID reminds me of the CTMX path.

0 · Reply

Avatar2312 Mar. 20 at 5:34 PM

$OVID Nice how it pushes against the trend today

0 · Reply

ReversalTrack Mar. 20 at 4:30 PM

Something is brewing on ticker JAGU 🚨🚀 One of the most explosive signals is setting up on the daily. Uranium+Rare earth play with news . War changes everything especially energy. ⚛️ Uranium = energy independence + national security Don't sleep on ticker JAGU!! $JDZG $KMRK $ZKH $OVID hot looks.

0 · Reply

JrsTrading Mar. 20 at 4:16 PM

$OVID OVID just upgraded isn't a speculative biotech Its an institutionally backed momentum biotech!! 💵💵

0 · Reply

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Mar 18, 2026, 5:02 PM EDT - 3 days ago

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

Mar 18, 2026, 10:01 AM EDT - 3 days ago

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Mar 18, 2026, 6:05 AM EDT - 3 days ago

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 18, 2026, 6:00 AM EDT - 3 days ago

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Feb 25, 2026, 7:00 AM EST - 24 days ago

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Jan 26, 2026, 11:01 PM EST - 7 weeks ago

Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots

Dec 18, 2025, 8:00 AM EST - 3 months ago

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Dec 2, 2025, 7:00 AM EST - 3 months ago

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Nov 12, 2025, 7:00 AM EST - 4 months ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Oct 3, 2025, 12:52 PM EDT - 6 months ago

Ovid Therapeutics Inc. - Special Call

Oct 3, 2025, 7:05 AM EDT - 6 months ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:00 AM EDT - 6 months ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Aug 13, 2025, 8:00 AM EDT - 7 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Jul 23, 2025, 8:30 AM EDT - 8 months ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jun 25, 2025, 8:00 AM EDT - 9 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

May 13, 2025, 8:00 AM EDT - 11 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Feb 27, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 1 year ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 12, 2024, 11:55 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 1 year ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 1 year ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jun 17, 2024, 8:58 AM EDT - 1 year ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Jun 17, 2024, 6:55 AM EDT - 1 year ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

May 14, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 9, 2024, 10:48 AM EDT - 2 years ago

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

SupremeElite Mar. 22 at 12:33 AM

$OVID

0 · Reply

LamboRush Mar. 21 at 3:25 PM

$OVID solid move so far

0 · Reply

FriendOfmy Mar. 21 at 4:23 AM

$OVID Offering at $2.01 folks ! Be careful folks pps will head back down to low 2’s

0 · Reply

Doom_Gloom_AR Mar. 20 at 11:31 PM

$OVID rerate time!

0 · Reply

AltradoLinguini Mar. 20 at 7:57 PM

$OVID This thing feels like it’s really about to blow into AH with virtually no major volume resistance because it’s so under the radar by comparison to peers. GLTA! 🍀🍀🍀

0 · Reply

anachartanalyst Mar. 20 at 6:02 PM

$OVID https://anachart.com/wp-content/uploads/ana_temp/1774029712_soc-img.jpg

0 · Reply

luccichio Mar. 20 at 5:56 PM

$OVID reminds me of the CTMX path.

0 · Reply

Avatar2312 Mar. 20 at 5:34 PM

$OVID Nice how it pushes against the trend today

0 · Reply

ReversalTrack Mar. 20 at 4:30 PM

0 · Reply

JrsTrading Mar. 20 at 4:16 PM

$OVID OVID just upgraded isn't a speculative biotech Its an institutionally backed momentum biotech!! 💵💵

0 · Reply

lucabrix Mar. 20 at 3:58 PM

$OVID is a 10$ stock!

0 · Reply

michaelhearn Mar. 20 at 3:28 PM

$OVID could spike to 5 very soon

0 · Reply

JeaFlor Mar. 20 at 3:28 PM

$OVID biotech range looks compressed enough to matter and the upside gets cleaner with confirm

0 · Reply

topstockalerts Mar. 20 at 3:21 PM

$OVID under the radar biotech type, reacts to catalysts. Quiet until it’s not.

0 · Reply

LIVE_Trading Mar. 20 at 2:50 PM

$OVID here

0 · Reply

FoxyDreams Mar. 20 at 2:09 PM

•@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of traders on this platform. •If you’re not following yet, you’re missing out. It takes 2 seconds and it’s completely free. 💎 $SLMT $OVID $NSPR $CAST ** on watch

0 · Reply

LIVE_Trading Mar. 20 at 1:54 PM

$OVID at support to bounce

0 · Reply